Insulin and Glucagon Peptide Market Trends: Brand Competition, Tech Trade-offs, and Global Supply Chain Analysis
Published: July 13, 2026 01:57
Author: Julia Clayton
Abstract: The insulin and glucagon peptide market is driven by rising diabetes prevalence and biosimilar adoption. Brand competition centers on efficacy and safety trade-offs, with rapid-acting analogs (e.g., Lispro) offering superior postprandial control versus long-acting formulations (e.g., Degludec) for basal stability. Global supply chains face API sourcing vulnerabilities, while regulatory certifications (FDA, EMA) remain critical for market access. Key trends include hybrid delivery devices and cold-chain logistics optimization, shaping a $45B+ industry poised for 8% CAGR growth through 2030.